Topic
Compounding pharmacy
Everything we've written on Compounding pharmacy — 9 articles covering the mechanism, the evidence, comparisons, and practical considerations.
9 articles
Compounding and complianceThe history of compounding pharmacy — from the 1990s to the modern peptide landscapeOn a Friday in September 2012, a patient in Tennessee developed what his physicians initially mistook for bacterial meningitis. By the weekend, clinicians at Vanderbilt University Medical Center were confused: the infection was not responding to antibiotics, the imaging was unusual, and the spinal fluid was not showing the bacterial pattern they expected. By the following week, they had identified the organism. It was Exserohilum rostratum, a common mold found in soil and plant matter. It had no business being in anyone's spinal cord. Tracing backward, investigators found the same fungus in patients in other states — Tennessee, Michigan, Virginia, Florida — all of whom had received epidural steroid injections for back pain in recent weeks. All of them had received the same methylprednisolone acetate preparation. All of it came from one facility in Framingham, Massachusetts: the New England Compounding Center.10 min readCompounding and complianceCompounding pharmacy quality variation — what's actually different from one pharmacy to anotherYou assume a licensed pharmacy is a licensed pharmacy. The license hangs on the wall, the state board approved the operation, the pharmacist passed their boards. The peptide you're getting from a licensed compounding pharmacy in one state should be the same quality as the peptide from a licensed pharmacy in another state. That assumption is wrong, and the degree to which it's wrong is something the wellness marketing around compounded peptides almost never discusses.10 min readCompounding and complianceFDA enforcement actions against peptide companies — what's happened and what it teachesThe warning letter arrives and the company's website goes dark. Maybe the FAQ page stays up for a few days with an explanation about "regulatory review." Maybe the domain just stops loading. Users who have been relying on that vendor for their supply find themselves scrambling, posting in forums, asking where else to go. The regulatory action that triggered it was months or years in development. For the users, it arrives as a sudden disruption. They had no warning because the vendor had no incentive to provide one.10 min readCompounding and complianceGray market vs compounding pharmacy — the supply chain distinction that matters mostAnyone who has spent time evaluating peptide options has arrived at the same question eventually, even if they didn't frame it this way: where is this actually coming from, and what does that mean? Two websites side by side, similar compound names, similar descriptions of mechanisms and expected effects, sometimes similar visual design. One costs substantially more and requires a prescription and a clinical consultation. One costs less, ships immediately, no prescription required. The price and convenience comparison is obvious. The supply chain comparison — the question of what these two purchase paths actually represent in terms of quality, legality, and accountability — is not stated anywhere on either site in a way that makes it easy to evaluate.4 min readCompounding and complianceThe peptide budget question — what reasonable monthly spend looks likeYou've started doing the math and something isn't adding up. The clinical consultation was one cost, the labs were another, and now you're looking at the actual prescription and trying to figure out whether this number is reasonable, inflated, or if you're missing something about how this whole thing is priced. The range you've encountered — from discussions of $50-a-month protocols to clinics advertising programs at several hundred monthly — spans too wide to evaluate without some framework for what you're actually paying for at each level.8 min readCompounding and complianceThe COA gaming problem — why "third-party tested" doesn't always mean what you thinkWhen a peptide company says "third-party tested," you probably picture an independent laboratory that received a sample of the exact product you're about to buy, ran it through meaningful analytical instruments, and confirmed that what's on the label is what's in the vial — correct identity, correct concentration, acceptable purity, and, for injectables, absence of the contaminants that matter for safety. That picture is accurate for some products. It is not accurate for a significant portion of the peptide market, and the gap between the marketing claim and the actual quality practice is large enough to affect decisions.9 min readCompounding and compliancePeptide harm reduction — the framework for those who will proceed regardlessYou've read the disclaimers. You know that clinician-supervised use through a licensed compounding pharmacy is the recommended path. You've decided you're going to proceed anyway — maybe because cost or access makes supervised use impractical, maybe because you've made a personal autonomy calculation, maybe because you've done enough research that you've decided the risk-benefit ratio is acceptable to you without formal oversight. This piece is not going to talk you out of that. It's going to tell you how to reduce the harm in the situation you've chosen.9 min readCompounding and complianceWhat "research peptide" labels really mean — and why they matter for what you're buyingYou're looking at two product pages side by side. Both sell the same compound — same name, similar molecular descriptions, roughly similar concentrations. One is priced at forty dollars. The other, from a licensed compounding pharmacy, requires a prescription and costs four times that. Both are described as "BPC-157" or "Tirzepatide" or whatever you went looking for. The cheaper one has a small line of text near the bottom of the page, easy to miss in the usual scan: "For research purposes only. Not for human consumption. Not intended for diagnostic or therapeutic use." You wonder if that language is just legal boilerplate, something every company puts up to cover themselves. It isn't.9 min readCompounding and complianceWhy peptide companies disappear — and what that tells you about the marketYou found a supplier two or three years ago. The products seemed reliable, the customer service was responsive, the pricing was reasonable. You built a routine around them. Then one day you go to reorder and the site resolves to a parking page. The email address returns undeliverable. The Instagram account that used to post compound breakdowns and founder updates has been deleted or gone silent. If you search the company name, you find nothing recent — maybe a thread on a forum where several other people are asking the same question. They're gone.9 min read